Role of plasma XXXX level in detecting @entity548 following blunt @entity1661 .

@entity1 @entity548 @entity3265 @entity1661 @entity3511 @entity204 @entity130
BACKGROUND: Blunt @entity3511 is a leading cause of @entity204 in @entity130 @entity1 . A reliable test predicting @entity548 would be a novel method. The study objective was to assess the diagnostic accuracy of plasma @entity3265 in detection of @entity548 in @entity1 with blunt @entity1661 (BAT). MATERIALS AND METHODS: In this observational study, all @entity1 suffering from BAT, referred to our university teaching hospital included. The levels of @entity3265 were measured at the time of emergency department admission and 1 h after initial treatment. Demographic data, vital signs, and venous blood gas reports were recorded. Findings of contrast-enhanced abdominopelvic computed tomography scan and laparotomy were assumed as a gold standard for @entity3511 . RESULTS: A total of 104 @entity1 was enrolled in the study. 15 @entity1 (14.4%) had @entity548 and the mean plasma @entity3265 level in this group was significantly higher than the other @entity1 on admission time (101.73    5.41  g/dL vs. 47.36    26.31  g/dL, P < 0.001). On receiver-operator characteristic curve analysis, in cutoff point of 89  g/dL, the sensitivity, specificity, positive and negative likelihood ratios were 100% (95% confidence interval [CI], 79.6-100), 93.26% (95% CI, 86-96.8), 14.83 (95% CI, 6.84-32.12), and 0, respectively. CONCLUSION: The study findings suggest the measurement of @entity3265 level at the time of admission in the @entity1 with BAT would be a useful test predicting @entity548 . Furthermore, decrease in the @entity3265 level could be a useful marker for monitoring response to treatment in these @entity1 .
